All In Biotech

Drug Trial Radar · NCT07561554

Phase I Study of HSK42360-Na in Solid Tumors With BRAF V600 Mutation

A Phase I, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of HSK42360-Na in Patients With BRAF V600 Mutation Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 20, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

159

Planned (sponsor's estimate)

Start

Mar 6, 2026

Primary completion

Dec 2, 2028

Study completion Dec 2, 2028

Sponsor

Sponsor type
Industry
First posted
May 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and PD of HSK42360-Na when given orally in patients with active BRAF V600 mutation locally advanced or metastatic Solid Tumors.

Conditions

  • Solid Tumors (Phase 1)

Interventions

  • HSK42360-NaDrug

    Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MTDTime frame: Up to approximately 52 months
  2. DLTsTime frame: Up to approximately 52 months
  3. AEsTime frame: Up to approximately 52 months
  4. RP2DTime frame: Up to approximately 52 months
  5. ECOG Performance Status ScaleTime frame: Up to approximately 52 months
  6. Karnofsky Performance Scale, KPSTime frame: Up to approximately 52 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing TianTan Hospital,Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.